ONO-9054   Click here for help

GtoPdb Ligand ID: 9875

Synonyms: sepetaprost
Compound class: Synthetic organic
Comment: Agonist at both the prostanoid FP and EP3 receptors that has clinical efficacy as an ocular hypotensive agent [1-2,4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 85.22
Molecular weight 482.25
XLogP 4.03
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(OC(=O)CCCC1CCC2C(OC1)CC(C2C=CC(COc1cc(F)ccc1F)O)O)C
Isomeric SMILES CC(OC(=O)CCC[C@H]1CC[C@H]2[C@@H](OC1)C[C@H]([C@@H]2/C=C/[C@H](COc1cc(F)ccc1F)O)O)C
InChI InChI=1S/C26H36F2O6/c1-16(2)34-26(31)5-3-4-17-6-9-21-20(23(30)13-24(21)32-14-17)10-8-19(29)15-33-25-12-18(27)7-11-22(25)28/h7-8,10-12,16-17,19-21,23-24,29-30H,3-6,9,13-15H2,1-2H3/b10-8+/t17-,19+,20+,21+,23+,24-/m0/s1
InChI Key BKVUSNOUTQMSBE-XCMGCKIWSA-N
No information available.
Summary of Clinical Use Click here for help
ONO-9054 has completed Phase 2 clinical NCT02083289 trial in patients with ocular hypertension or open-angle glaucoma. Trial results indicate that ONO-9054 is more effective in reducing intraocular pressure and has a longer lasting effect than latanoprost (isopropyl ester) (Xalatan) [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02083289 A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG) Phase 2 Interventional Ono Pharmaceutical Co. Ltd